{"abstract": "After rebuffing an unsolicited $10 billion offer by Amgen that it deemed too low, the maker of cancer drugs hired an investment bank to seek new suitors.", "web_url": "https://dealbook.nytimes.com/2013/06/30/onyx-explores-a-sale-after-rebuffing-a-bid-by-amgen/", "snippet": "After rebuffing an unsolicited $10 billion offer by Amgen that it deemed too low, the maker of cancer drugs hired an investment bank to seek new suitors.", "lead_paragraph": "9:06 p.m. | Updated ", "print_section": "B", "print_page": "3", "source": "The New York Times", "multimedia": [], "headline": {"main": "Onyx Rejects Amgen\u2019s Takeover Bid, Then Places Itself on the Market", "kicker": "DealBook", "content_kicker": null, "print_headline": "Maker of Cancer Drugs Rejects Takeover Bid, Then Places Itself on the Market", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "organizations", "value": "AMGEN INC", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Onyx Pharmaceuticals", "rank": 3, "major": "N"}], "pub_date": "2013-06-30T16:23:07+0000", "document_type": "article", "news_desk": "", "section_name": "Business Day", "byline": {"original": "By Michael J. de la Merced and Andrew Pollack", "person": [{"firstname": "Michael", "middlename": "J.", "lastname": "de la Merced", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/ef3c6cd4-0fea-51cd-af53-162e28f90778", "word_count": 831, "uri": "nyt://article/ef3c6cd4-0fea-51cd-af53-162e28f90778"}